Home » Stocks » SRGA

Surgalign Holdings, Inc. (SRGA)

Stock Price: $2.04 USD -0.07 (-3.32%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
After-hours: $2.09 +0.05 (2.45%) Jan 20, 5:45 PM
Market Cap 171.75M
Revenue (ttm) 236.08M
Net Income (ttm) -132.19M
Shares Out 73.21M
EPS (ttm) -1.80
PE Ratio n/a
Forward PE 526.32
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $2.04
Previous Close $2.11
Change ($) -0.07
Change (%) -3.32%
Day's Open 2.11
Day's Range 2.02 - 2.11
Day's Volume 860,859
52-Week Range 1.49 - 4.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

Commercial launch of ViBone® Moldable, a next generation moldable cellular bone matrix product in the US Commercial launch of ViBone® Moldable, a next generation moldable cellular bone matrix ...

GlobeNewsWire - 1 week ago

DEERFIELD, Ill., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery including through the applicatio...

Seeking Alpha - 1 week ago

Company is working off a solid base, and the balance sheet is clean. The technicals are ultra oversold especially on the long-term chart.

GlobeNewsWire - 1 month ago

DEERFIELD, Ill., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a leading global pure-play spine company focused on advancing spine surgery and improving patient ou...

GlobeNewsWire - 1 month ago

DEERFIELD, Ill., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery including through the applicatio...

GlobeNewsWire - 2 months ago

Updated agreement expands availability of ViBone® Moldable, a next generation moldable cellular bone matrix product Updated agreement expands availability of ViBone® Moldable, a next generatio...

GlobeNewsWire - 2 months ago

DEERFIELD, Ill., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery, including through the applicati...

GlobeNewsWire - 2 months ago

DEERFIELD, Ill., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery, including through the applicati...

GuruFocus - 2 months ago

According to the GuruFocus All-in-One Screener as of Nov. 5, the following medical technology stocks are popular among gurus.

Other stocks mentioned: ANIP, VNDA, PETS, SRDX
GlobeNewsWire - 2 months ago

DEERFIELD, Ill., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery, including through the applicati...

GlobeNewsWire - 2 months ago

Acquisition Delivers on Commitment to the Promise of Digital Surgery to Improve Patient Outcomes

GlobeNewsWire - 3 months ago

Commitment to the Promise of Digital Surgery to Improve Patient Outcomes Commitment to the Promise of Digital Surgery to Improve Patient Outcomes

About SRGA

Surgalign Holdings, a medical technology company, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It offers coflex interlaminar stabilization device, an implant for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; SImmetry sacroiliac joint fusion system, which decreases in opioid use, pain, and disability; and Fortilink IBF system with TETRAfuse ?3D technology. The company's implants are used in the fields of orthopedic, spine, sports medicine, plas... [Read more...]

Industry
Medical Devices
IPO Date
Aug 10, 0200
Stock Exchange
NASDAQ
Ticker Symbol
SRGA
Full Company Profile

Financial Performance

In 2019, SRGA's revenue was $308.38 million, an increase of 9.99% compared to the previous year's $280.36 million. Losses were -$211.64 million, 6,676.9% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for SRGA stock is "Strong Buy." The 12-month stock price forecast is 5.60, which is an increase of 174.51% from the latest price.

Price Target
$5.60
(174.51% upside)
Analyst Consensus: Strong Buy